In 2020,Yao et al. screened the anti-cancer potential of grincamycin-B (162), a marine natural product, against GBM cell lines.100 Grincamycin-B (162) showed potentialcell inhibition against the U251 and 091214 GBM cell lines, with IC50 = 2.04 ± 0.24 and 3.11 ± 0.25 μM, respectively.Further biological evaluation revealed that grincamycin-B (162) targets CSCs in GBM by targeting the RHOA and PI3K/Akt signalingpathways (Figure 41C). Here, AKT1 is linked to glioblastoma.